首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

MELANOMA RESEARCH
ISSN：0960-8931

MELANOMA RESEARCH

MELANOMA RES
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：较慢,6-12周
新锐分区：医学4区
年发文量：69
影响因子：1.9
JCR分区：Q3

基本信息

黑色素瘤研究是一个完善的国际论坛，传播有关黑色素瘤的新发现。该杂志的目的是促进从事该领域的人之间的信息交流水平。黑色素瘤研究旨在鼓励对实验和临床研究的知情和平衡观点，并扩大和促进不同专业领域的研究者之间的沟通和知识交流。这将促进转化研究的发展。新的临床结果的报告和新的治疗剂和免疫疗法的效果和毒性将通过快速出版的简短通信给予重点。因此，黑色素瘤研究寻求提出一个连贯的和最新的帐户的所有方面的研究有关黑色素瘤。因此，该杂志的范围很广，涵盖了遗传学、分子生物学、生物化学、细胞生物学、光生物学、病理学、免疫学等学科领域的基础研究和应用研究，以及影响黑色素瘤预防、诊断和治疗的临床肿瘤学进展。
0960-8931SCIE/Scopus收录
1.9
点击查看最新影响趋势>
1.8
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
DERMATOLOGY 皮肤病学
3区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
4区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：DERMATOLOGY
SCIE
Q3
53/96
学科：MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q3
132/195
学科：ONCOLOGY
SCIE
Q3
243/328
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：DERMATOLOGY
SCIE
Q3
65/96
学科：MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q3
121/195
学科：ONCOLOGY
SCIE
Q3
216/328
67
69
点击查看年发文量趋势图>
7%0较慢,6-12周-医学-皮肤病学
5.3%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
86.96%19.9%-
CiteScore：3.00
SJR：0.657
SNIP：0.574
学科类别分区排名百分位
大类：Medicine
小类：Dermatology
Q2
61 / 147
大类：Medicine
小类：Oncology
Q3
250 / 415
大类：Medicine
小类：Cancer Research
Q3
174 / 233

期刊高被引文献

18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000541
Expression and clinical significance of S100 family genes in patients with melanoma
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000512
Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000542
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000520
MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000524
Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000628
Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000560
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000653
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000586
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000589
Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000617
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
来源期刊：Melanoma researchDOI：10.1097/cmr.0000000000000642
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000633
Primary malignant melanotic melanoma and hypomelanotic melanoma of the female urethra: case series and a review of the literature in China
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000521
Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000588
Loss of miR-155 upregulates WEE1 in metastatic melanoma
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000545
Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000510
Ultraviolet radiation and cutaneous melanoma: a historical perspective
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000609
Unmet information needs of patients with melanoma in Germany
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000464
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000605
Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000629
Severe Gastrointestinal Toxicity of MEK Inhibitors.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000618
MRI enables accurate diagnosis and follow-up in uveal melanoma patients after vitrectomy
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000568
External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000643
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000537
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000483
Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000578
Combination of &ohgr;-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000564
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000654
Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000594
A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000582
Prognostic role of NRAS isoforms in Chinese melanoma patients
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000557
TRAF2 and FKBP51 as possible markers for identification of suitable melanoma tumors for tumor necrosis factor-&agr; inhibition
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000553
Eruptive cherry angiomas and skin melanoma: a fortuitous association?
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000563
Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000645
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000504
Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000593
Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000621
Molecular and immunohistochemical analyses of uveal melanoma patient cohort
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000523
Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000635
Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000576
Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000528
The alternatively spliced RECK transcript variant 3 is a predictor of poor survival for melanoma patients being upregulated in aggressive cell lines and modulating MMP gene expression in vitro
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000650
Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000597
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000632
Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000652
New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000627
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients
来源期刊：Melanoma ResearchDOI：10.1097/CMR.0000000000000625
Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000646
Are patients in haemodialysis good candidates for immunotherapy treatment?
来源期刊：Melanoma researchDOI：10.1097/CMR.0000000000000616

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACSMS HEALTH & FITNESS JOURNAL封面

ACSMS HEALTH & FITNESS JOURNAL

学科领域：医学
影响因子：1.8
中科院分区： 4区
ACTA BIOQUIMICA CLINICA LATINOAMERICANA封面

ACTA BIOQUIMICA CLINICA LATINOAMERICANA

学科领域：医学
影响因子：0.1
中科院分区： 4区
Acta Cardiologica Sinica封面

Acta Cardiologica Sinica

学科领域：医学
影响因子：1.8
中科院分区： 4区
Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca封面

Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca

学科领域：医学
影响因子：0.4
中科院分区： 4区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
DERMATOLOGY 皮肤病学
3区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
4区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
DERMATOLOGY 皮肤病学
4区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
4区
ONCOLOGY 肿瘤学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
DERMATOLOGY 皮肤病学
4区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
4区
ONCOLOGY 肿瘤学
4区
否
否